Capital Advisors Ltd’s Enanta Pharmaceuticals ENTA Stock Holding History

Capital Advisors Ltd’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-71	Closed	-$1K	–	1339
2023 Q3	$1K	Buy	+71	New	+$1.14K	﹤0.01%	1115

Other funds holding ENTA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Advisors Ltd's ENTA Position: Q4 2023 in Review

Capital Advisors Ltd sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 71 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in ENTA in Q3 2023 and held it in 1 quarter. The position peaked at $1K in Q3 2023. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

Capital Advisors Ltd reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Capital Advisors Ltd sold 71 Enanta Pharmaceuticals shares in Q4 2023, an estimated $1K.
Capital Advisors Ltd first reported a position in Enanta Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Capital Advisors Ltd's Enanta Pharmaceuticals position peaked at $1K in Q3 2023.
105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Capital Advisors Ltd's 13F filing for Q4 2023, filed 2 Feb 2024.